Comparison of outcomes with elranatamab and real world treatments in the UK for triple class exposed relapsed and refractory multiple myeloma Quiz

John is a 65-year-old male diagnosed with triple class exposed, relapsed and refractory multiple myeloma (TCE RRMM). He has undergone multiple prior therapies including proteasome inhibitors, immunomodulatory drugs, and anti-CD38 antibodies. Currently, he is being evaluated for further treatment options after disease progression on pomalidomide plus dexamethasone. He has no significant comorbidities and is insured under the NHS.

Question: Based on the recent evidence comparing elranatamab to real-world UK treatments for TCE RRMM, what is the most significant clinical benefit of initiating elranatamab therapy for John?

Mary is a 70-year-old female with triple class exposed relapsed and refractory multiple myeloma. She has been treated with multiple regimens including pomalidomide plus dexamethasone, which was her last therapy. She is now considering options and asks about the expected outcomes with newer therapies versus standard care available in the NHS.

Question: What median progression-free survival (PFS) can Mary expect with current standard NHS treatments compared to elranatamab based on UK real-world data?

David is a 68-year-old patient with triple class exposed relapsed/refractory multiple myeloma who has been started on elranatamab. He inquires about the survival benefits of this treatment compared to other available therapies in the UK NHS.

Question: How should a pharmacist counsel David regarding the overall survival (OS) benefit of elranatamab based on the adjusted analyses from recent UK studies?